Tarsus Pharmaceuticals to buy Alkeus Pharmaceuticals

Tarsus Pharmaceuticals to buy Alkeus Pharmaceuticals
TARS AI Soars 76% as Buyback Plan and NVIDIA Inception Program Fuel Investor Confidence
TARS Protocol Achieves Major Milestones With Growing Adoption And Token Burn
Tarsus Pharmaceuticals seesaws amid report Alcon interest has cooled
Tarsus Pharmaceuticals gains amid takeover speculation
Here’s why the TARS AI token price is soaring
3.5BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US87650L1035
CUSIP
87650L103
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-
Book Value
8.01
Dividend Share
-
Dividend Yield
-
Earnings Share
-1.08
Wall Street Target Price
98.89
EPS Estimate Current Year
-5.79
EPS Estimate Next Year
-0.50
EPS Estimate Current Quarter
-0.196
EPS Estimate Next Quarter
-1.8167
Most Recent Quarter
-
Revenue TTM
606,331,008
Gross Profit TTM
501,264,000
EBITDA
-46,195,000
Profit Margin
-7.67%
Return On Assets TTM
-5.49%
Return On Equity TTM
-13.68%
Revenue Per Share TTM
14.121
Qtly Revenue Growth YOY
69.40%
Diluted Eps TTM
-1.08
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
75
Price Sales TTM
5.6582
Price Book MRQ
10.1051
Enterprise Value Revenue
5
Enterprise Value EBITDA
-3
903.08
3.20%227.40
2.97%965.00
0.55%314.92
0.35%900.30
0.00%139.16
0.00%528.21
-4.77%355.10
-2.26%34.64
-2.01%153.70
-1.47%